Given its demonstrated efficacy in the treatment of adult patients with moderate to severe CD and lower risk adverse effect profile when compared with nonselective α4 integrin inhibitors (14), it has become an increasingly popular treatment for patients who have not responded to anti-TNFα therapies. This evidence concerns the gene TNF and Cowden disease.